RhumbLine S&P 500 Equal Weighted Index (S:0P00003H1F)
92.73
-1.54
(-1.63%)
USD |
Oct 31 2024
Returns Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Key Stats
| Maximum Management Fee | Annualized Total Returns Since Inception (Daily) | Alpha (vs Category) (3Y) | Forecasted Dividend Yield |
|---|---|---|---|
| -- | -- | -- | -- |
| Total Market Value (Net) | Beta (vs Category) (3Y) | Max Drawdown (Since Inception) | Fwd Dividend Yield (Long) |
| Upgrade | Upgrade | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| General | |
| Security Type | |
| Equity Style | |
| Fixed Income Style | |
| Broad Asset Class | |
| Broad Category | |
| Category Name | |
| Category Index | |
| Global Category Name | |
| YCharts Categorization | US Large Cap Blend |
| YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
| Fund Owner Firm Name | |
| Prospectus Benchmark Index | |
| S&P 500 TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| 100.0% | |
| Manager Tenure | |
| Julie Lee | 21.27 yrs |
| Jeff Kusmierz | 17.85 yrs |
| Antonio Ballestas | 5.16 yrs |
| Andrew Zagarri | 3.62 yrs |
Annual Total Returns Versus Peers
As of November 23, 2024.
Asset Allocation
| Type | % Net | % Long | % Short |
|---|---|---|---|
| Cash | -- | -- | -- |
| Stock | -- | -- | -- |
| Bond | -- | -- | -- |
| Convertible | -- | -- | -- |
| Preferred | -- | -- | -- |
| Other | -- | -- | -- |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Invesco S&P 500® Equal Weight ETF | 0.55% | 185.53 | 0.79% |
| ResMed Inc | 0.24% | 243.78 | 0.07% |
| Gap Inc | 0.24% | 24.87 | 12.84% |
| Hologic Inc | 0.24% | 78.97 | 0.32% |
| Eli Lilly and Co | 0.23% | 748.01 | -0.25% |
| The AES Corp | 0.23% | 13.04 | -1.58% |
| Masco Corp | 0.23% | 79.01 | 0.87% |
| Lam Research Corp | 0.23% | 72.64 | -0.67% |
| IDEXX Laboratories Inc | 0.23% | 417.24 | -0.31% |
| West Pharmaceutical Services Inc | 0.23% | 316.59 | -1.34% |
Fees & Availability
| Fees | |
| Negotiable Fee | No |
| Administrative Fee | -- |
| Maximum Management Fee | -- |
| Prospectus Custodian Fee | -- |
| Trustee Fee | -- |
| Purchase Details | |
| Open to New Investors | No |
| Open to Existing Investors | No |
| Minimum Initial Investment | -- |
| Minimum Subsequent Investment | -- |
Basic Info
| Investment Strategy | |
| General | |
| Security Type | |
| Equity Style | |
| Fixed Income Style | |
| Broad Asset Class | |
| Broad Category | |
| Category Name | |
| Category Index | |
| Global Category Name | |
| YCharts Categorization | US Large Cap Blend |
| YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
| Fund Owner Firm Name | |
| Prospectus Benchmark Index | |
| S&P 500 TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| 100.0% | |
| Manager Tenure | |
| Julie Lee | 21.27 yrs |
| Jeff Kusmierz | 17.85 yrs |
| Antonio Ballestas | 5.16 yrs |
| Andrew Zagarri | 3.62 yrs |
Fundamentals
| Number of Holdings | -- |
| Stock | |
| Weighted Average PE Ratio | -- |
| Weighted Average Price to Sales Ratio | -- |
| Weighted Average Price to Book Ratio | -- |
| Weighted Median ROE | -- |
| Weighted Median ROA | -- |
| Forecasted Dividend Yield | -- |
| Forecasted PE Ratio | -- |
| Forecasted Price to Sales Ratio | -- |
| Forecasted Price to Book Ratio | -- |
Fund Details
| Key Dates | |
| Inception Date | -- |
| Last Annual Report Date | -- |
| Last Prospectus Date | -- |
| Attributes | |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |